Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 3/20 | 0.56 |
| ▸ | TLR2 | O60603 | 2/20 | 0.53 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7780471 | 1.00 | PRCP (0.56) | PRCPTLR2DPP7NAAAGAA | |
| SCHEMBL7780443 | 1.00 | PRCP (0.56) | PRCPTLR2DPP7NAAAGAA | |
| SCHEMBL9659933 | 1.00 | PRCP (0.56) | PRCPTLR2DPP7NAAAGAA | |
| SCHEMBL9659930 | 1.00 | PRCP (0.56) | PRCPTLR2DPP7NAAAGAA | |
| SCHEMBL7533568 | 1.00 | PRCP (0.56) | PRCPTLR2DPP7NAAAGAA | |
| SCHEMBL7533567 | 1.00 | PRCP (0.56) | PRCPTLR2DPP7NAAAGAA | |
| SCHEMBL9658685 | 1.00 | PRCP (0.56) | PRCPTLR2DPP7NAAAGAA | |
| SCHEMBL7782934 | 1.00 | PRCP (0.56) | PRCPTLR2DPP7NAAAGAA | |
| SCHEMBL7780475 | 1.00 | PRCP (0.56) | PRCPTLR2DPP7NAAAGAA | |
| SCHEMBL293572 | 1.00 | PRCP (0.56) | PRCPTLR2DPP7NAAAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108440487-A | A kind of application process based on the catalyst of synthesizing annular carbonate under low-temperature atmosphere-pressure | 武汉艾奥立化学科技有限公司 | 2018-08-24 | — | — | CN | disclosed |
| US-9962369-B2 | Methods and compositions for transdermal delivery | SPRAYABLE HOLDINGS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9949952-B2 | Methods and compositions for transdermal delivery | SPRAYABLE HOLDINGS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| EP-3116489-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY | Yu, Benjamin M. (US) | 2017-01-18 | — | — | EP | disclosed |
| US-20160317435-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY OF CAFFEINE IN THE FORM OF SOLUTIONS OR SUSPENSIONS | SPRAYABLE HOLDINGS, INC. | 2016-11-03 | — | — | US | disclosed |
| CN-105693817-A | Tripeptide compound and preparation method and application thereof | 西北大学 | 2016-06-22 | — | — | CN | disclosed |
| EP-2964231-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY OF CAFFEINE IN THE FORMS OF SOLUTION OR SUSPENSION | Yu, Benjamin M. (US) | 2016-01-13 | — | — | EP | disclosed |
| US-9211249-B2 | Methods and compositions for transdermal delivery of caffeine in the form of solutions or suspensions | SPRAYABLE HOLDINGS, INC. | 2015-12-15 | — | — | US | disclosed |
| US-20150258065-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY | SPRAYABLE HOLDINGS, INC. | 2015-09-17 | — | — | US | disclosed |
| WO-2015138486-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY | YU BENJAMIN M (US) | 2015-09-17 | — | — | WO | disclosed |
| US-20150250884-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY | SPRAYABLE HOLDINGS, INC. | 2015-09-10 | — | — | US | disclosed |
| WO-2014138708-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY OF CAFFEINE IN THE FORMS OF SOLUTION OR SUSPENSION | YU BENJAMIN M (US) | 2014-09-12 | — | — | WO | disclosed |
| US-20140256749-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY OF CAFFEINE IN THE FORM OF SOLUTIONS OR SUSPENSIONS | SPRAYABLE HOLDINGS, INC. | 2014-09-11 | — | — | US | disclosed |
| EP-0309624-B1 | COMPOSITION FOR ENHANCING PERCUTANEOUS ADMINISTRATION OF MEDICINE | NITTO DENKO CORPORATION (JP) | 1992-03-11 | — | — | EP | disclosed |
| EP-0309624-A1 | Composition for enhancing percutaneous administration of medicine | NITTO DENKO CORPORATION (JP) | 1989-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150258065-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY | MTNR1A, MTNR1B, CYP27B1 | PRCP 3559/4885TLR2 1542/4885DPP7 2858/4885 |
| US-20140256749-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY OF CAFFEINE IN THE FORM OF SOLUTIONS OR SUSPENSIONS | TES, CCR7, CES2 | PRCP 3056/4885TLR2 2625/4885DPP7 3438/4885 |
| US-20150250884-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY | VDR, CYP27B1, TTPA | PRCP 4173/4885TLR2 1590/4885DPP7 3248/4885 |
| US-20160317435-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY OF CAFFEINE IN THE FORM OF SOLUTIONS OR SUSPENSIONS | TES, CCR7, CES2 | PRCP 3056/4885TLR2 2625/4885DPP7 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.